Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02437136 · ClinicalTrials.gov registry record · Phase 1
Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)
A Phase 1 study of Non-Small Cell Lung Cancer and Melanoma, sponsored by Syndax Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 191
- Enrollment target
- 11
- Study locations
NCT02437136 is a Phase 1 study of Non-Small Cell Lung Cancer and Melanoma that has completed, run by Syndax Pharmaceuticals. The registered enrollment target is 191 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (71% lower). The trial reports 11 study locations across 8 states.
The verdict
NCT02437136, a Phase 1 study of Non-Small Cell Lung Cancer and Melanoma, has completed, sponsored by Syndax Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 191 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of this study is to determine the safety and tolerability of entinostat used in combination with pembrolizumab in participants with NSCLC. Additionally, the purpose of the study is to assess how effective entinostat and pembrolizumab are in combination in participants with NSCLC, Melanoma, and Mismatch-Repair Proficient CRC.
Conditions Studied
Interventions
- DRUG pembrolizumab
- DRUG entinostat
Study Locations (11)
Maryland
- University of Maryland, Marlene and Stewart Greenbaum Cancer Center - Baltimore
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore
New York
- Roswell Park Cancer Institute - Buffalo
- Memorial Sloan Kettering Cancer Center - New York
Tennessee
- Sarah Cannon Research Institute - Nashville
- Vanderbilt University Medical Center - Nashville
Connecticut
- Yale University - New Haven
Georgia
- Emory University - Atlanta
Massachusetts
- Dana Farber Cancer Institution - Boston
North Carolina
- The University of North Carolina at Chapel Hill - Chapel Hill
Pennsylvania
- St Luke's University Health Network - Easton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 191 participants |
| Start Date | 2015-08-26 |
| Est. Completion | 2022-09-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02437136
The ClinicalTrials.gov registry entry for NCT02437136 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 191 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (71% lower). The listed sponsor is Syndax Pharmaceuticals, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which pembrolizumab is the first listed.
NCT02437136 reports 11 study locations spanning 8 distinct geographic areas - top geographies include Maryland, New York, Tennessee.
Frequently Asked Questions
What is clinical trial NCT02437136 about?
NCT02437136 is a clinical study titled "Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)". The purpose of this study is to determine the safety and tolerability of entinostat used in combination with pembrolizumab in participants with NSCLC. Additionally, the purpose of the study is to assess how effective entinostat and pembrolizumab are in combination in participants with NSCLC, Melanom...
What is the current status of trial NCT02437136?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 191 participants. The study started on 2015-08-26. Estimated completion is 2022-09-29.
What conditions does trial NCT02437136 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Melanoma, Mismatch Repair-Proficient Colorectal Cancer.
What interventions are being tested in trial NCT02437136?
The interventions under investigation include: pembrolizumab (DRUG), entinostat (DRUG).
Who is sponsoring clinical trial NCT02437136?
This trial is sponsored by Syndax Pharmaceuticals, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02437136 being conducted?
This trial has 11 study locations across Connecticut, Georgia, Maryland, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.